Could a short course of radiation before surgery spare more breast tissue?

NCT ID NCT02186470

Completed Disease control Sponsor: Ohio State University Comprehensive Cancer Center Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This pilot study tested whether giving a high dose of focused radiation (APBI) to the tumor before surgery is feasible for older women with early-stage, hormone-sensitive breast cancer. Twenty-two participants received radiation followed by a lumpectomy. The goal was to see if this approach could shrink the tumor and reduce the amount of healthy tissue removed, while keeping side effects manageable.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: accelerated partial breast irradiation (APBI)
What this could lead to: If successful, this approach could allow some patients to have less extensive surgery and better cosmetic outcomes after breast cancer treatment.
What could go wrong: This is a very small, early feasibility study with only 22 participants, so results may not apply to all patients. Radiation before surgery can cause side effects like skin reactions or changes in healing.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ESTROGEN-RECEPTOR-POSITIVE BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

breast cancer breast ductal adenocarcinoma breast mucinous carcinoma breast neoplasm breast papillary carcinoma estrogen-receptor positive breast cancer invasive ductal breast carcinoma invasive tubular breast carcinoma medullary breast carcinoma progesterone-receptor positive breast cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ESTROGEN-RECEPTOR-POSITIVE BREAST CANCER INVASIVE DUCTAL BREAST CARCINOMA INVASIVE DUCTAL BREAST CARCINOMA WITH PREDOMINANT INTRADUCTAL COMPONENT MEDULLARY DUCTAL BREAST CARCINOMA WITH LYMPHOCYTIC INFILTRATE MUCINOUS DUCTAL BREAST CARCINOMA PAPILLARY DUCTAL BREAST CARCINOMA PROGESTERONE-RECEPTOR-POSITIVE BREAST CANCER STAGE IA BREAST CANCER STAGE IB BREAST CANCER TUBULAR DUCTAL BREAST CARCINOMA

Contacts and locations

Locations

Ohio State University Comprehensive Cancer Center

Columbus, Ohio, 43210, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.